美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Militia Long/Short Equity ETF

38.03

+0.50001.33%

盤後：38.170.1400+0.37%18:21 EST

成交量：42.50萬

成交額：1,613.18萬

市值：3.48億

市盈率：- -

高：38.24

開：37.87

低：37.68

收：37.53

52周最高：38.24

52周最低：25.85

股本：916.00萬

流通股本：916.00萬

量比：0.88

換手率：4.64%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

澤璟製藥-U事件點評：ZG006授權給艾伯維澤速寧獲批上市

甬兴证券有限公司

5000億！一戰封神，他是中國最成功的美國人

優赫得在華拓展第六個適應症，去年上半年銷售額突破22億美金

德曲妥珠單抗胃癌新適應證獲批，填補臨牀治療空白

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ORR"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.03,"timestamp":1770670800000,"preClose":37.53,"halted":0,"volume":425048,"hourTrading":{"tag":"盘后","latestPrice":38.17,"preClose":38.03,"latestTime":"18:21 EST","volume":264,"amount":9981.90072,"timestamp":1770679289766,"change":0.14,"changeRate":0.003681,"amplitude":0.012359},"delay":0,"changeRate":0.01332267519317879,"floatShares":9160000,"shares":9160000,"eps":0,"marketStatus":"盤後交易","change":0.5,"latestTime":"02-09 18:41:02 EST","open":37.865,"high":38.24,"low":37.675,"amount":16131791.487759998,"amplitude":0.015055,"askPrice":38.46,"askSize":5100,"bidPrice":37.7,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1770685200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":37.53,"sharesOutstanding":9160000,"nav":36.92,"aum":338187200,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":37.73,"preClose":37.53,"latestTime":"08:44 EST","volume":126,"amount":4754.529864,"timestamp":1770644686174,"change":0.2,"changeRate":0.005329,"amplitude":0.000799},"postHourTrading":{"tag":"盘后","latestPrice":38.17,"preClose":38.03,"latestTime":"18:21 EST","volume":264,"amount":9981.90072,"timestamp":1770679289766,"change":0.14,"changeRate":0.003681,"amplitude":0.012359},"volumeRatio":0.878824,"impliedVol":0.0683,"impliedVolPercentile":0.2174},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9160000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.878824,"shares":9160000,"dividePrice":0,"high":38.24,"amplitude":0.015055,"preClose":37.53,"low":37.675,"week52Low":25.85,"pbRate":"--","week52High":38.24,"institutionHeld":0,"latestPrice":38.03,"committee":-0.961538,"eps":0,"divideRate":0,"volume":425048,"delay":0,"ttmEps":0,"open":37.865,"prevYearClose":34.16,"prevWeekClose":37.53,"prevMonthClose":36.48,"prevQuarterClose":34.16,"fiveDayClose":36.49,"twentyDayClose":35.38,"sixtyDayClose":32.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606259515","title":"澤璟製藥-U事件點評：ZG006授權給艾伯維 澤速寧獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2606259515","media":"甬兴证券有限公司","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606259515?lang=zh_tw&edition=fundamental","pubTime":"2026-01-25 09:40","pubTimestamp":1769305230,"startTime":"0","endTime":"0","summary":"2025 年 11 月，ZG006 单药治疗晚期NEC 获 CDE 纳入突破性治疗品种公示名单，有望通过附条件批准实现早日上市。此外ZG006 联合 PD-1/PD-L1 抑制剂及化疗用于小细胞肺癌的临床试验已获批。吉卡昔替尼新入医保、泽速宁获批上市吉卡昔替尼作为首个获批国产治疗骨髓纤维化的 JAK 抑制剂成功纳入医保。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260125094033a4529cab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260125094033a4529cab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002270589.USD","LU1093756325.SGD","LU0545039389.USD","LU2087621335.USD","SG9999015978.USD","LU0310800379.SGD","IE00BJJMRZ35.SGD","LU0949170772.SGD","LU0689472784.USD","IE0002141913.USD","LU1496350502.SGD","LU1732800096.USD","LU1003077747.HKD","ORR","LU1023059063.AUD","LU1551013342.USD","LU1983299246.USD","BK4550","IE0009355771.USD","LU0289961442.SGD","LU0912757837.SGD","ABBV","IE00BN8TJ469.HKD","LU2112291526.USD","LU0122379950.USD","LU1037948541.HKD","LU0069063385.USD","LU2133065610.SGD","LU1496350171.SGD","IE00BFTCPJ56.SGD","LU1057294990.SGD","BK4533","LU0310799852.SGD","IE00BJT1NW94.SGD","LU2237443382.USD","LU1929549753.HKD","IE00BVYPNW00.USD","SG9999011175.SGD","LU0795875086.SGD","LU2089283258.USD","SG9999015986.USD","LU1244550577.SGD","LU1934455194.USD","LU2237443978.SGD","LU2468319806.SGD","LU0965508806.USD","LU1291159041.SGD","LU0234572021.USD","LU1989772923.USD","LU0256863811.USD"],"gpt_icon":0},{"id":"2606125812","title":"5000億！一戰封神，他是中國最成功的美國人","url":"https://stock-news.laohu8.com/highlight/detail?id=2606125812","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606125812?lang=zh_tw&edition=fundamental","pubTime":"2026-01-25 08:34","pubTimestamp":1769301264,"startTime":"0","endTime":"0","summary":"文 | 华商韬略 韩翔州2010年，旧金山的一次私人聚会上，已在中国创业有成的美国人欧雷强，结识了已在美国功成名就的中国人王晓东。终于在年底，他们决定一起冒险：在中国建立一家世界级的生物科技公司，在中国做创新药卖给全世界。作为一名连续创业者，欧雷强的履历堪称完美。事实证明，中国没有辜负欧雷强的眼光。欧雷强预见到，中国的监管环境即将迎来一场有利于创新药的剧变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769137313695679325","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["PFS","BMS","LU1251922891.USD","BK1161","LU1969619763.USD","LU0588546209.SGD","BK4211","LU1719994722.HKD","BK1500","BK1588","LU1303224171.USD","BK4195","LU1770034418.SGD","LU0307460666.USD","LU2328871848.SGD","ASH","BK1583","LU2463526074.USD","06160","BK4109","ORR"],"gpt_icon":0},{"id":"2605034473","title":"優赫得在華拓展第六個適應症，去年上半年銷售額突破22億美金","url":"https://stock-news.laohu8.com/highlight/detail?id=2605034473","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605034473?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 17:13","pubTimestamp":1769159628,"startTime":"0","endTime":"0","summary":"2024 年全球已获批上市的 17 款 ADC 药物合计销售额达百亿美金，其中第一三共的德曲妥珠单抗表现尤为突出，2024 年销售额达到 34.8 亿美元、同比增长 52%。根据阿斯利康2025年上半年财报，其自身销售额为12.6亿美元，增长38%；包括合作伙伴第一三共报告的销售额在内，总销售额为22.9亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769159310955231385","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["OS","BK4195","BK4231","BK4080","ORR","BK4211","PFS","ADC","BK4097"],"gpt_icon":0},{"id":"2605989254","title":"德曲妥珠單抗胃癌新適應證獲批，填補臨牀治療空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2605989254","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605989254?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 19:18","pubTimestamp":1769080687,"startTime":"0","endTime":"0","summary":"由阿斯利康和第一三共共同开发与商业化的优赫得（英文商品名：Enhertu，通用名：注射用德曲妥珠单抗）今天获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627553572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","BK4195","ORR","BK4080","BK4097","PFS","BK4211","ADC","OS"],"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}